Truist Financial Issues Pessimistic Forecast for Arcus Biosciences (NYSE:RCUS) Stock Price

Posted by George Bondi on Nov 7th, 2026

Arcus Biosciences (NYSE:RCUS – Get Free Report) had its price objective cut by research analysts at Truist Financial from $41.00 to $40.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial‘s price target suggests a potential upside of 119.21% from the company’s current price.

RCUS has been the topic of a number of other reports. Wedbush cut their target price on Arcus Biosciences from $49.00 to $45.00 and set an “outperform” rating on the stock in a research report on Thursday. Citigroup boosted their price objective on Arcus Biosciences from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday, October 21st. JPMorgan Chase & Co. assumed coverage on shares of Arcus Biosciences in a research note on Wednesday, October 14th. They set an “overweight” rating and a $41.00 price objective for the company. The Goldman Sachs Group reaffirmed a “buy” rating and set a $42.00 price objective on shares of Arcus Biosciences in a research note on Friday, August 7th. Finally, Morgan Stanley set a $23.00 target price on shares of Arcus Biosciences in a report on Monday, August 10th. Twelve research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $39.36.

Check Out Our Latest Report on Arcus Biosciences

Arcus Biosciences Price Performance

Shares of NYSE RCUS traded up $0.56 during trading on Thursday, hitting $18.25. The company had a trading volume of 1,055,346 shares, compared to its average volume of 2,615,364. Arcus Biosciences has a 52 week low of $17.43 and a 52 week high of $31.74. The business’s 50-day moving average is $23.74 and its 200 day moving average is $24.54. The company has a market cap of $2.32 billion, a P/E ratio of -5.03 and a beta of 1.04. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.82 and a current ratio of 3.82.

Arcus Biosciences (NYSE:RCUS – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.11). The company had revenue of $9.00 million for the quarter, compared to the consensus estimate of $7.58 million. Arcus Biosciences had a negative return on equity of 89.54% and a negative net margin of 393.16%. The business’s revenue was down 65.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.27) earnings per share. Equities research analysts predict that Arcus Biosciences will post -3.55 earnings per share for the current fiscal year.

Insider Transactions at Arcus Biosciences

In other news, CAO Alexander Azoy sold 2,827 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $30.00, for a total value of $84,810.00. Following the completion of the sale, the chief accounting officer owned 39,581 shares in the company, valued at $1,187,430. This represents a 6.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.60% of the stock is currently owned by company insiders.

Institutional Trading of Arcus Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp purchased a new stake in Arcus Biosciences in the 2nd quarter worth about $16,741,000. Legal & General Group Plc acquired a new stake in Arcus Biosciences during the 2nd quarter worth about $5,906,000. Corient Private Wealth LP acquired a new stake in Arcus Biosciences during the 2nd quarter worth about $1,823,000. BlackRock Inc. purchased a new position in Arcus Biosciences during the 2nd quarter valued at about $506,113,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Arcus Biosciences during the 1st quarter valued at about $1,862,000. Institutional investors and hedge funds own 92.89% of the company’s stock.

Key Headlines Impacting Arcus Biosciences

Here are the key news stories impacting Arcus Biosciences this week:

Positive Sentiment: Leerink Partners raised its price target to $49 from $46 and maintained an “outperform” rating, signaling confidence in Arcus’s potential. Read More.
Negative Sentiment: Arcus reported a third-quarter loss of $1.00 per share, wider than analysts’ expected loss of $0.92. Revenue of $9 million exceeded expectations, but was down 65.4% year over year. The earnings-per-share miss may weigh on sentiment. Read More.
Negative Sentiment: Wedbush lowered its price target to $45 from $49, while retaining an “outperform” rating. Truist also trimmed its target, to $40 from $41, but kept its “buy” rating. The reductions temper the positive outlook, though both firms still see substantial potential upside. Read More. · Read More.

About Arcus Biosciences

(Get Free Report)

Arcus Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company uses its research platform to discover and advance medicines designed to target immune suppression and other biological mechanisms involved in tumor growth.

Arcus’s oncology pipeline has included antibody-based and small-molecule therapies aimed at targets such as TIGIT, PD-1, CD73, and the adenosine A2A and A2B receptors. Its key development programs have included domvanalimab, zimberelimab, quemliclustat, and etrumadenant, which have been evaluated in clinical studies across several cancer types, including lung, gastrointestinal, and colorectal cancers.

Founded in 2015 and headquartered in Hayward, California, Arcus conducts research and clinical-development activities intended to support potential commercialization in international markets.